98%
921
2 minutes
20
Despite the improvement of psoriasis treatment achieved with the use of biological therapies, some patients still require hospitalization. A retrospective study was conducted including patients affected by psoriasis hospitalized at Fondazione Policlinico Agostino Gemelli IRCCS in Rome, from 1 January 2012 to 1 August 2023, to describe the psoriasis patient journey. Of the 2.223 patients with psoriasis, 1,500 had it as the primary diagnosis. Some 93.2% (2,071/2,223) of patients were affected by plaque psoriasis, 4.8% (108/2,223) presented with erythrodermic psoriasis, and 2.0% (44/2,223) had generalized pustular psoriasis. 1,455/2,223 (65.5%) reported in their medical history psoriatic arthritis, and 771/2,223 (34.7%) hypertension; 328/2,223 (14.8%) psoriatic patients accessed the emergency department (ED), 291 of whom (13.1%) were subsequently hospitalized in different inpatient clinics, while 37 (1.6%) were then discharged. Inpatient clinic admission after ED was required more frequently in generalized pustular or erythrodermic psoriasis (47.7% and 38% respectively) compared with plaque psoriasis (11%). Patients admitted to an inpatient clinic after ED had a longer recovery compared with those admitted electively to an inpatient clinic (13.6 days vs 7.7 days, p < 0.001). Only 490/2,223 (20.9%) patients were admitted to a dermatology service. This study showed a shift in patient management rather than a reduction in hospitalizations.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11995728 | PMC |
http://dx.doi.org/10.2340/actadv.v105.42503 | DOI Listing |
Adv Ther
September 2025
Bristol Myers Squibb, Princeton, NJ, 08540, USA.
Background And Objectives: Deucravacitinib, a first-in-class, oral, selective, allosteric tyrosine kinase 2 inhibitor, demonstrated efficacy across the primary endpoint and all key secondary endpoints in the phase 2 PAISLEY SLE trial in patients with active systemic lupus erythematosus (SLE). Here, we describe 2 phase 3 trials [POETYK SLE-1 (NCT05617677), POETYK SLE-2 (NCT05620407)] which will assess the efficacy and safety of deucravacitinib in patients with active SLE. These phase 3 trials have been designed to replicate the successful elements of the phase 2 trial, including its glucocorticoid-tapering strategy and disease activity adjudication.
View Article and Find Full Text PDFAdv Sci (Weinh)
September 2025
Department of Dermatology, Air Force Medical Center, PLA, Beijing, 100142, China.
Psoriasis is an inflammatory dermatological condition challenging to treat and prone to recurrence. The pathogenesis of psoriasis is closely associated with metabolic disorders, while therapies targeting the dysregulated metabolism in psoriasis remain limited. Therefore, exploring the pathogenesis of psoriasis and identifying potential metabolic therapeutic targets is imperative.
View Article and Find Full Text PDFCureus
August 2025
Pathology, Dermatology, University of Mississippi Medical Center, Jackson, USA.
Molluscum contagiosum (MC) is a common cutaneous viral infection predominantly affecting children. In this report, we present the case of a five-year-old male with recurrent MC who developed the beginning of the end (BOTE) sign, reflecting an inflammatory response that correlates with imminent lesion resolution. The patient's lesions were monitored without further intervention following the appearance of the BOTE sign, and complete resolution was documented in roughly two months.
View Article and Find Full Text PDFCureus
August 2025
Dermatology, Hôpital Privé Francheville, Perigueux, FRA.
Risankizumab (RZB) is a humanized monoclonal antibody that selectively targets interleukin-23 (IL-23). It has proven particularly effective in treating psoriasis, a common chronic inflammatory skin disease. However, its use remains poorly documented in certain populations, including patients with a history of solid organ transplantation or recent/active malignancy.
View Article and Find Full Text PDFCureus
August 2025
Ophthalmology, Henry Ford Health System, Detroit, USA.
This report discusses a case of diagnosing neurosyphilis in a non-classical presentation with confounding test results needing a deliberate and multidisciplinary diagnostic approach. A 38-year-old immunocompetent male presented with uveitis and a skin rash. Although serology was positive for syphilis (rapid plasma reagin 1:128), it was also positive for tuberculosis, and a dermatology consult identified the rash as psoriasis, creating a complex diagnostic picture.
View Article and Find Full Text PDF